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We retrospectively investigated patients with small-cell lung cancer with or without interstitial lung 
disease (ILD). Response rates and median progression-free survival of 1st-line chemotherapy in 
patients with or without preexisting ILD was not significantly different. However, pneumonitis 
associated with chemotherapy was significantly increased in patients with preexisting ILD, and 





Background: In Japan, iatrogenic acute exacerbation (AE) of interstitial lung disease (ILD) is a 
serious complication in patients with lung cancer and simultaneous ILD. Some reports suggest that 
patients with ILD and small cell lung cancer (SCLC) might benefit from chemotherapy, but the 
influence of ILD on prognosis is unclear. Patients and Methods: Retrospective study of patients 
with SCLC with or without ILD. Between April 2006 and March 2011, 122 SCLC patients receiving 
platinum-based combination chemotherapy participated. Results: Twenty-eight patients (23.0%) had 
ILD at diagnosis. Pneumonitis associated with chemotherapy including AE-ILD was significantly 
increased in patients with preexisting ILD (P = .0001; 8/28 vs. 2/94,). In patients receiving 
chemotherapy alone, response rates and median progression-free survival of 1st-line chemotherapy 
in patients with or without preexisting ILD was not significantly different (P = .26; 20/26 vs. 52/60 
and P = .089; 4.4 months vs. 5.4 months, respectively). Median overall survival (OS) of all patients 
was 15.5 months, but those without preexisting ILD survived significantly longer (P = .0010; 17.8 
months vs. 10.7 months). Multivariate analysis revealed that performance status of 0 or 1 (hazard 
ratio [HR], 0.19; 95% confidence interval [CI], 0.10 – 0.37; P < .0001), limited disease (HR, 0.42; 
95% CI, 0.23 – 0.73; P = .0017), and no preexisting ILD (HR, 0.36; 95% CI, 0.19 – 0.69; P = .0027) 
were significantly associated with longer OS. Conclusion: Patients with SCLC and ILD might 
benefit from chemotherapy but preexisting ILD is an independent prognostic factor for poorer 
survival. 
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Lung cancer remains the leading cause of cancer-related death in Japan as well as in Western 
countries. Although the incidence of small cell lung cancer (SCLC) compared to other lung cancer is 
relatively low (approximately 15% of all), prognosis remains poor, even for early stage SCLC. From 
the time of diagnosis, median survival for limited disease (LD)-SCLC and extensive disease 
(ED)-SCLC is 15-20 and 8-13 months, respectively.
1-3
 
Interstitial lung disease (ILD) is characterized by fibrosis of the interstitial compartment clinically 
manifesting as dyspnea. ILD, especially idiopathic pulmonary fibrosis (IPF), seems to be associated 
with lung carcinogenesis. The incidence of lung cancer in patients with IPF is higher than in the 
general population.
4-7
 ILD is usually characterized by slowly progressive respiratory insufficiency. 
However, the clinical course of ILD is often complicated by acute deterioration without an 
identifiable cause, called “acute exacerbation” (AE-ILD), and these processes are associated with 
poor prognoses.
8-11
 Moreover, in patients with lung cancer together with ILD, AE-ILD frequently 
occurs after anticancer therapy including chemotherapy. However, there are few reports on 
chemotherapy for lung cancer with ILD.
12-15
 If left untreated, patients with SCLC rarely survive 
longer than a few months, but 60-80% respond to chemotherapy, which dramatically prolongs 
survival compared to the best supportive care.
3
 Although Minegishi et al. suggested that patients 
with SCLC and ILD might benefit from chemotherapy.
12,14
 the influence of ILD on prognosis has not 




Materials and methods 
Patients 
One hundred and forty-one Japanese patients with untreated SCLC were diagnosed between April 
2006 and March 2011 at Kyoto University Hospital. Of these, 19 received best supportive care alone, 
and the remaining 122 received platinum-based combination chemotherapy (platinum plus etoposide 
or irinotecan) as 1st-line chemotherapy. These latter 122 patients participated in this study, which 
was approved by the Ethics Committee of Kyoto University Graduate School and Faculty of 
Medicine. 
 
Patients’ characteristics and tumor responses 
We retrospectively analyzed patients’ backgrounds and tumor responses. Staging was performed 
based on the Verterans Administration Lung Study Group system,
1
 and responses were assessed 
every 2 cycles of chemotherapy according to the Response Evaluation Criteria in Solid Tumor 
version 1.0.
16
 First-line chemotherapy was performed for up to 6 cycles at the discretion of the 
attending physician. 
 
Preexisting interstitial lung disease 
We classified preexisting ILD into two types, either idiopathic interstitial pneumonia (IIP) or not IIP. 
The latter included ILD associated with collagen-vascular disease (CVD), sarcoidosis, and other 
syndromes. IIP itself was classified into two types, IPF and non-IPF. For the diagnosis of IIP, we 
used the American Thoracic Society/European Respiratory Society consensus classification.
7
 None 
of the patients was surgically biopsied; thus, ILD was diagnosed by 2 physicians based on 
high-resolution computed tomography (HRCT) and clinical features before treatment for SCLC. 
Five patients underwent bronchoscopy (bronchoalveolar lavage and transbronchial lung biopsy) for 
more detailed examination of ILD. Pulmonary function test data in 91 patients (74.6%) were 
available, and these are referred to here. 
 
Acute exacerbation of interstitial lung disease and pneumonitis 
 AE-ILD was diagnosed according to published criteria:
14,15,17
 (a) subjective worsening of dyspnea 
within the last month; (b) new ground-glass opacities or consolidation on chest radiography or 
HRCT; (c) hypoxemia with a decline of 10 mmHg in PaO2 from the previous level; (d) no evidence 
of infection (assessed by negative respiratory culture and serologic test results for respiratory 
pathogens); and (e) no clinical evidence of pulmonary embolism, congestive heart failure, or 
pneumothorax as a cause of acute worsening. For patients without preexisting ILD, pneumonitis is 
considered equivalent to AE-ILD. Therefore, the grade was assessed as pneumonitis according to the 





The univariate relationship between each independent variable was examined using the χ
2
 test or 
Fisher´s exact test if there were five or fewer observations in a group. Overall survival (OS) was 
defined as the time from the initiation of 1st-line chemotherapy until death from any cause. 
Progression-free survival (PFS) was defined as the time from the initiation of chemotherapy to the 
first observation of disease progression or death from any cause. OS and PFS were analyzed using 
the Kaplan-Meier method and compared among groups by the log-rank test. To identify prognostic 
factors, a Cox proportional hazards model was used for univariate and multivariate analyses. The 
multivariate analysis was performed with adjustment for covariates, including age, gender, smoking 
status, Eastern Cooperative Oncology Group Performance Status (ECOG PS), stage, and preexisting 
ILD. All tests were two-tailed and P values less than 0.05 were considered statistically significant. 





The clinical characteristics of 122 patients are summarized in Table 1. All patients were Japanese, 
including 94 males (77.0%) and 28 females (23.0%), with a median age of 69 years (range, 33 – 85 
years). Many patients (95/122, 77.9%) were heavy smokers (>40 pack-years) and had ECOG PS of 0 
or 1 (99/122, 81.1%). The primary stage of 53 patients (43.4%) was LD, with 69 (56.6%) ED. 
Twenty-eight patients (23.0%) had ILD at SCLC diagnosis and 9 of them (32.1%) had already been 
followed by their physicians as ILD patients before they were diagnosed with lung cancer. This high 
incidence of ILD seemed to be because many of the patients with ILD were referred to us from other 
hospitals but followed-up in our hospital. Six of these 9 patients (66.7%) had LD, whereas only 5 of 
the remaining 19 (26.3%) had LD (P = .095 by Fisher´s exact test). In patients with both ILD and 
lung cancer, 21 (75.0%) had idiopathic interstitial pneumonia (IIP) (10 IPF and 11 non-IPF), 6 
(21.4%) had ILD associated with CVD and one (3.6%) had ILD associated with sarcoidosis. Two 
patients were on corticosteroid for ILD at baseline when they were diagnosed with SCLC. 
Pulmonary function tests data were available in 23 of 28 patients with ILD (82.1%) and 68 of 94 
patients without ILD (72.3%) (P = .34 by Fisher´s exact test). 
 A comparison of patients with and without preexisting ILD is summarized in Table 2. There were 
no significant differences between the two groups in age (P = .16 by χ
2
 test), gender (P = .83 by χ
2
 
test), smoking status (P = .35 by χ
2
 test), ECOG PS (P = 1.00 by Fisher´s exact test), or stage (P 
= .61 by χ
2
 test). Although there were no significant differences in obstructive disorders (forced 
expiratory volume in one second/forced vital capacity <70%) (P = .43 by χ
2
 test), restrictive 
disorders (percent vital capacity; %VC <80%) were present significantly more frequently in patients 
with preexisting ILD (P = .042 by Fisher´s exact test). Significantly more patients without 
preexisting ILD received thoracic radiotherapy combined with chemotherapy (P = .0038 by Fisher´s 
exact test). Considering LD-SCLC, only 2 of 11 patients with preexisting ILD received thoracic 
radiotherapy together with chemotherapy, compared to 33 of 42 without preexisting ILD (P = .0004 
by Fisher´s exact test; 18.2% vs. 78.6%). The response rate of patients without preexisting ILD to 
initial treatment tended to be higher than that of patients with preexisting ILD, but this difference did 
not achieve significance (P = .063 by χ
2
 test; 85/93 vs. 22/28). Similarly, for patients who received 
chemotherapy alone, there were no significant differences in response rates (P = .26 by χ
2
 test; 52/60 
vs. 20/26). Sixty of 91 patients without preexisting ILD (65.9%) and 12 of 27 patients with 
preexisting ILD (44.4%) received subsequent chemotherapy (P = .044 by χ
2
 test).  
When patients were suspected of having pneumonitis, including AE-ILD, associated with 
chemotherapy, all received HRCT, sputum culture tests, blood culture tests, and serologic tests (for 
beta-glucan, cytomegalovirus antigen, tumor markers, brain natriuretic peptide, KL-6, and surfactant 
protein-D). In addition, 2 patients underwent bronchoscopy; however, this was not possible in the 
remaining patients due to hypoxia. From these examinations, 10 patients were diagnosed with 
9 
 
pneumonitis associated with chemotherapy, and 2 with preexisting ILD were diagnosed with 
opportunistic infections (pneumocystis jirovecii pneumonia and aspergillus pneumonia). 
Pneumonitis, including AE-ILD, associated with chemotherapy, occurred significantly more 
frequently in patients with preexisting ILD (P = .0001 by Fisher´s exact test). Pneumonitis 
associated with 1st-line chemotherapy was significantly increased in patients with preexisting ILD 
(P = .0024 by Fisher´s exact test; 5/28 vs. 1/94). Five of these 6 patients received combination 
chemotherapy with platinum and etoposide and one received platinum and irinotecan. Similarly, 
pneumonitis associated with subsequent chemotherapy also occurred significantly more often in 
patients with preexisting ILD (P = .013 by Fisher´s exact test; 3/12 vs. 1/60). Three of these 4 
patients received amrubicin and one received paclitaxel. Preexisting ILD was significantly 
associated with pneumonitis in most chemotherapy regimens (Table 3). Patients with IPF had 
AE-ILD complications as frequently as patients with ILD other than IPF (P = 1.00 by Fisher´s exact 
test; 3/10 vs. 5/18). None of the 10 patients was on corticosteroids at baseline and all received 
high-dose corticosteroid as well as treatment with broad spectrum antibiotics until the possibility of 
infection was ruled out. Corticosteroid therapy was tapered. However, hHalf of the 10 patients died 
from pneumonitis. Only 2 of the 10 had mild pneumonitis (grade 2) and could receive subsequent 
treatment. 
Median OS of all patients (n = 122) was 15.5 months, but patients without preexisting ILD had a 
significantly longer OS than those with preexisting ILD (P = .0010 by log-rank test; 17.8 months vs. 
10.7 months) (Fig. 1). The results of univariate and multivariate analyses for OS are summarized in 
Table 4A. Based on the multivariate analysis, age (<75/>75 years), gender (female/male), smoking 
status (<40/>40 pack-years), ECOG PS (0 or 1/2 or 3), stage (LD/ED), preexisting ILD (no/yes), 
ECOG PS of 0 or 1 (HR, 0.19; 95% CI, 0.10 – 0.37; P < .0001), LD (HR, 0.42; 95% CI, 0.23 – 0.73; 
P = .0017), and no preexisting ILD (HR, 0.36; 95% CI, 0.19 – 0.69; P = .0027) were all significantly 
associated with longer OS (Table 4A). Stage (LD/ED) was strongly associated with initial treatment 
decisions (thoracic radiotherapy with chemotherapy/chemotherapy alone). Therefore, this variable 
was not included in this analysis. In addition, the variables of pulmonary function tests were also not 
included since they had some missing values. 
Next, we focused on patients receiving chemotherapy alone (n = 87). Median PFS on 1st-line 
chemotherapy was 5.3 months, with no significant differences between patients with or without 
preexisting ILD (P = .089 by log-rank test; 4.4 months vs. 5.4 months) (Fig. 2). In contrast, median 
OS of the 87 chemotherapy patients was 12.9 months but when stratified according to the presence 
of ILD it was significantly longer if there was no ILD (P = .027 by log-rank test; 13.1 months vs. 9.9 
months) (Fig. 3). The results of univariate and multivariate analyses for OS are summarized in Table 
4B. Based on the multivariate analysis, age (<75/>75 years), gender (female/male), smoking status 
(<40/>40 pack-years), ECOG PS (0 or 1/2 or 3), stage (LD/ED), preexisting ILD (no/yes), ECOG PS 
10 
 
of 0 or 1 (HR, 0.18; 95% CI, 0.095 – 0.36; P < .0001) and no preexisting ILD (HR, 0.44; 95% CI, 




Although small and retrospective, this study showed that preexisting ILD was significantly 
associated with worse prognosis in patients with SCLC. To the best of our knowledge, this is the first 
report that preexisting ILD is an independent prognostic factor for survival in SCLC. 
Considering only patients who received chemotherapy alone (no radiotherapy), this study 
documented no significant differences in response rate to 1st-line chemotherapy, or PFS, between 
patients with or without preexisting ILD. This indicates that patients with SCLC together with ILD 
might benefit from chemotherapy considering that when left untreated they rarely survive longer 
than a few months.
3
 In spite of this finding, this study showed that preexisting ILD is an independent 
prognostic factor for survival. One reason seemed to be that patients with preexisting ILD rarely 
received thoracic radiotherapy combined with chemotherapy even if the primary stage was LD. 
Some studies have shown that preexisting ILD is one of the risk factors for severe radiation 
pneumonitis and treatment-related death.
18,19
 Therefore, most patients with preexisting ILD do not 
receive thoracic radiotherapy in our hospital even if they have only LD. Focusing on these patients 
who only received chemotherapy, however, preexisting ILD also became an independent prognostic 
factor for survival. This seemed to be because approximate 20% of patients with preexisting ILD had 
AE-ILD as a complication and subsequent treatment was limited. In a Japanese case-controlled study, 
preexisting ILD was reported to be an independent risk factor for developing pneumonitis.
20
 In our 
study, although the number of patients was small, pneumonitis associated with chemotherapy also 
occurred significantly more frequently in patients with preexisting ILD. In addition, half of them 
died from pneumonitis and only 2 of these 10 patients received any subsequent treatment. This high 
mortality rate was similar to that seen in previous studies.
12-15,20
 In addition, opportunistic infections 
during immunosuppression and lower %VC of patients with preexisting ILD can also be associated 
with poor prognosis. 
In some patients, it can be difficult to differentiate pneumonitis, including AE-ILD, associated with 
chemotherapy from other diseases. For differential diagnosis of pneumonitis, there are various 
infectious diseases, congestive heart failure, thromboembolism, and progressive lymphangitic spread 
of the carcinoma that need to be excluded. Therefore, we routinely performed detailed examinations 
including HRCT, which is a useful modality for the diagnosis of pneumonitis. Nevertheless, the 
exact incidence of pneumonitis may be overdiagnosed, because radiological changes cannot 
specifically identify or diagnose histopathological changes. 
Combination chemotherapy with platinum and etoposide is considered to be the standard 1st-line 
chemotherapy regimen for SCLC.
21
 Recently, combination chemotherapy with platinum and 
irinotecan has been also proposed as a standard 1st-line chemotherapy regimen.
22,23
 Pulmonary 
toxicity, however, has been reported in patients given irinotecan.
24,25
 Therefore, Minegishi et al. 
suggested that combination chemotherapy with platinum and etoposide could be a candidate regimen 
12 
 
for treatment of patients with SCLC together with ILD. In our study, most patients with preexisting 
ILD did receive platinum plus etoposide (25/28, 89.3%), and 4 of these suffered AE-ILD as a 
complication (16.0%). This rate is similar to that reported in previous studies.
12-15
 Although patients 
with SCLC together with ILD may benefit from chemotherapy regimens such as platinum plus 
etoposide, chemotherapy should be administered carefully considering this high AE-ILD rate. 
Several clinical trials indicated that amrubicin exhibits significant activity against SCLC and can be 
effective as a 2nd-line regimen.
26,27
 However, severe pneumonitis associated with amrubicin has 
been reported and Yoh et al. recommended not administering this drug to patients with SCLC and 
ILD.
28
 Our study also noted a high rate of AE-ILD in patients with preexisting ILD who received 
amrubicin (2/9, 22.2%), similar to a previous report.
28
 Considering this high AE-ILD rate, it is 
controversial whether patients with SCLC and ILD benefit from amrubicin as a subsequent 
chemotherapy. Therefore, amrubicin should be administered with caution to selected patients with 
SCLC and ILD. 
Both etoposide and amrubicin are potent inhibitors of topoisomerase II, but one induced 
pneumonitis and the other not. The precise reason for this is unclear. Etoposide is a rather old drug 
evaluated during a period without HRCT; therefore, pneumonitis associated with etoposide, 
including subclinical, could be more frequent than beleived. We suggest another hypothesis; 
gefitinib and erlotinib are both epidermal growth factor receptor tyrosine kinase inhibitors but 
several reports have demonstrated successful treatment with erlotinib after gefitinib-induced 
pneumonitis.
29-31
 Therefore, we speculate that differences in the chemical structure can influence 




Although this was a small retrospective analysis, we show here that patients with SCLC together 
with ILD might benefit from chemotherapy but that preexisting ILD is an independent prognostic 
factor for survival. Patients with preexisting ILD rarely received thoracic radiotherapy and 
approximately 20% of such patients suffered from AE-ILD as a complication, which seems to be 




Clinical practice points 
Acute exacerbation (AE) of interstitial lung disease (ILD) is a serious complication in patients with 
lung cancer and simultaneous ILD. Some previous reports suggest that patients with ILD and small 
cell lung cancer (SCLC) might benefit from chemotherapy, but pneumonitis associated with 
chemotherapy including AE-ILD is significantly increased in patients with ILD. However, the 
influence of ILD on prognosis is unclear. In this study, we retrospectively investigated patients with 
SCLC with or without ILD. We show here that patients with SCLC together with ILD might benefit 
from chemotherapy but that preexisting ILD is an independent prognostic factor for survival. 
Patients with preexisting ILD rarely received thoracic radiotherapy and approximately 20% of such 
patients suffered from AE-ILD as a complication, which seems to be associated with poor prognosis. 
From these findings, patients with SCLC and ILD should be received chemotherapy, but caution 





1. Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2005; 366: 1385-96. 
2. Puglisi M, Dolly S, Faria A, et al. Treatment options for small cell lung cancer - do we have 
more choice? Br J Cancer 2010; 102: 629-38. 
3. Demedts IK, Vermaelen KY, van Meerbeeck JP. Treatment of extensive-stage small cell lung 
carcinoma: current status and future prospects. Eur Respir J 2010; 35: 202-15. 
4. Hubbard R, Venn A, Lewis S, et al. Lung cancer and cryptogenic fibrosing alveolitis. A 
population-based cohort study. Am J Respir Crit Care Med 2000; 161: 5-8. 
5. Park J, Kim DS, Shim TS, et al. Lung cancer in patients with idiopathic pulmonary fibrosis. Eur 
Respir J 2001; 17; 1216-9. 
6. Harris JM, Johnston ID, Rudd R, et al. Cryptogenic fibrosing alveolitis and lung cancer: the 
BTS study. Thorax 2010; 65: 70-6. 
7. American Thoracic Society; European Respiratory Society. American Thoracic 
Society/European Respiratory Society International Multidisciplinary Consensus Classification 
of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society 
(ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, 
June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 
165: 277-304. 
8. Collard HR, Moore BB, Flaherty KR, et al; Idiopathic Pulmonary Fibrosis Clinical Research 
Network Investigators. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit 
Care Med 2007; 176: 636-43. 
9. Kondoh Y, Taniguchi H, Kawabata Y, et al. Acute exacerbation in idiopathic pulmonary fibrosis. 
Analysis of clinical and pathologic findings in three cases. Chest 1993; 103: 1808-12. 
10. Hyzy R, Huang S, Myers J, et al. Acute exacerbation of idiopathic pulmonary fibrosis. Chest 
2007; 132: 1652-8. 
11. Papanikolaou IC, Drakopanagiotakis F, Polychronopoulos VS. Acute exacerbations of interstitial 
lung diseases. Curr Opin Pulm Med 2010; 16: 480-6. 
12. Minegishi Y, Takenaka K, Mizutani H, et al. Exacerbation of idiopathic interstitial pneumonias 
associated with lung cancer therapy. Intern Med 2009; 48: 665-72. 
13. Shukuya T, Ishiwata T, Hara M, et al. Carboplatin plus weekly paclitaxel treatment in non-small 
cell lung cancer patients with interstitial lung disease. Anticancer Res 2010; 30: 4357-61. 
14. Minegishi Y, Kuribayashi H, Kitamura K, et al. The Feasibility Study of Carboplatin Plus 
Etoposide for Advanced Small Cell Lung Cancer with Idiopathic Interstitial Pneumonias. J 
Thorac Oncol 2011; 6: 801-7. 
16 
 
15. Minegishi Y, Sudoh J, Kuribayasi H, et al. The safety and efficacy of weekly paclitaxel in 
combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial 
pneumonias. Lung Cancer 2011; 71: 70-4. 
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to 
treatment in solid tumors. European Organization for Research and Treatment of Cancer, 
National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl 
Cancer Inst 2000; 92: 205-16. 
17. Akira M, Hamada H, Sakatani M, et al. CT findings during phase of accelerated deterioration in 
patients with idiopathic pulmonary fibrosis. AJR Am J Roentgenol 1997; 168: 79-83. 
18. Makimoto T, Tsuchiya S, Hayakawa K, et al. Risk factors for severe radiation pneumonitis in 
lung cancer. Jpn J Clin Oncol 1999; 29: 192-7. 
19. Ohe Y, Yamamoto S, Suzuki K, et al. Risk factors of treatment-related death in chemotherapy 
and thoracic radiotherapy for lung cancer. Eur J Cancer 2001; 37: 54-63. 
20. Kudoh S, Kato H, Nishiwaki Y, et al. Interstitial lung disease in Japanese patients with lung 
cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 2008; 177: 1348-57. 
21. Sundstrøm S, Bremnes RM, Kaasa S, et al; Norwegian Lung Cancer Study Group. Cisplatin and 
etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in 
small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin 
Oncol 2002; 20: 4665-72. 
22. Noda K, Nishiwaki Y, Kawahara M, et al; Japan Clinical Oncology Group. Irinotecan plus 
cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J 
Med 2002; 346: 85-91. 
23. Lima JP, dos Santos LV, Sasse EC, et al. Camptothecins compared with etoposide in 
combination with platinum analog in extensive stage small cell lung cancer: systematic review 
with meta-analysis. J Thorac Oncol 2010; 5: 1986-97. 
24. Madarnas Y, Webster P, Shorter AM, et al. Irinotecan-associated pulmonary toxicity. 
Anticancer Drugs 2000; 11: 709-13. 
25. Michielin O, Udry E, Périard D, et al. Irinotecan-induced interstitial pneumonia. Lancet Oncol 
2004; 5: 322-4. 
26. Onoda S, Masuda N, Seto T, et al; Thoracic Oncology Research Group Study 0301. Phase II 
trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic 
Oncology Research Group Study 0301. J Clin Oncol 2006; 24: 5448-53. 
27. Inoue A, Sugawara S, Yamazaki K, et al. Randomized phase II trial comparing amrubicin with 
topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer 
Study Group Trial 0402. J Clin Oncol 2008; 26: 5401-6. 
17 
 
28. Yoh K, Kenmotsu H, Yamaguchi Y, et al. Severe interstitial lung disease associated with 
amrubicin treatment. J Thorac Oncol 2010; 5: 1435-8. 
29. Fukui T, Otani S, Hataishi R, et al. Successful rechallenge with erlotinib in a patient with 
EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease. 
Cancer Chemother Pharmacol 2010; 65: 803-6. 
30. Takeda M, Okamoto I, Makimura C, et al. Successful treatment with erlotinib after 
gefitinib-induced severe interstitial lung disease. J Thorac Oncol 2010; 5: 1103-4. 
28.31. Chang SC, Chamg CY, Chen CY, et al. Successful elotinib rechallenge after 




Figure 1.  
Kaplan-Meier curves of overall survival (OS) for patients with preexisting interstitial lung disease 
(ILD) vs. patients without preexisting ILD. The median OS of patients without preexisting ILD was 
significantly longer than that of patients with preexisting ILD (P = .0010 by log-rank test; 17.8 
months vs. 10.7 months). 
 
Figure 2. 
Kaplan-Meier curves of progression-free survival (PFS) for patients with preexisting interstitial lung 
disease (ILD) vs. patients without preexisting ILD. Patients received chemotherapy alone (n = 87). 
The median PFS of patients without preexisting ILD was preferentially but not significantly longer 
than that of patients with preexisting ILD (P = .089 by log-rank test; 4.4 months vs. 5.4 months). 
 
Figure 3.  
Kaplan-Meier curves of overall survival (OS) for patients with preexisting interstitial lung disease 
(ILD) vs. patients without preexisting ILD. Patients received chemotherapy alone (n = 87). The 
median OS of patients without preexisting ILD was significantly longer than that of patients with 
preexisting ILD (P = .027 by log-rank test; 13.1 months vs. 9.9 months). 
Table 1. Patients characteristics (n = 122). 
Patients characteristics Number of patients % 
Age (years)   
 Range  33 – 85 
 Median 69 
 Mean ± SD 67.8 ± 9.2 
Gender   
 Male 94 77.0 
 Female 28 23.0 
Smoking status   
 <40 pack-years 95 77.9 
 >40 pack-years 27 22.1 
ECOG PS   
0 49 40.2 
1 50 41.0 
2 16 13.1 
3 7 5.7 
Stage   
 LD 53 43.4 
 ED 69 56.6 
ILD   
 No 94 77.1 
 IIP 21 17.2 
 ILD associated with CVD 6 4.9 
 ILD associated with sarcoidosis 1 0.8 
％VC (%)   
 <80% 9 7.4 
 >80% 82 67.2 
 Not evaluated 31 25.4 
FEV1/FVC   
 <70% 42 34.4 
 >70% 49 40.2 
 Not evaluated 31 25.4 
Initial treatment   
 Thoracic radiotherapy with chemotherapy 37 30.3 
 Platinum plus etoposide 53 43.5 
 Platinum plus irinotecan 32 26.2 
Response   
 Complete response 23 18.9 
 Partial response 84 68.9 
 Stable disease 9 7.4 
 Progressive disease 5 4.1 
 Not evaluated 1 0.8 
Abbreviations; SD = standard deviation; ECOG PS = Eastern Cooperative Oncology Group 
Performance Status; LD = limited disease; ED = extensive disease; ILD = interstitial lung 
disease; %VC = percent vital capacity; FEV1 = forced expiratory volume in one second; FVC = 
forced vital capacity; IIP = idiopathic interstitial pneumonia; CVD = collagen-vascular disease. 
Table
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Age    
  <75 years 17 70 
.16 
  >75 years 11 24 
Gender    
  Male 22 72 
.83 
  Female 6 22 
Smoking status    
  <40 pack-years 8 19 
.35 
  >40 pack-years 20 75 
ECOG PS    
0 or 1 23 76 
1.00 
2 or 3 5 18 
Stage    
  LD 11 42 
.61 
  ED 17 52 
 %VC    
  <80% 5 4 
.042* 
  >80% 18 64 
  Not evaluated 5 26  
 FEV1/FVC    
  <70% 9 35 
.43 
  >70% 14 33 
  Not evaluated 5 26  
Initial treatment    
 Thoracic radiotherapy with chemotherapy 2 33 
.0038* 
 Chemotherapy alone 26 61 
First-line chemotherapy regimen    
 Platinum with etoposide 25 65 
.048* 
 Platinum with irinotecan 3 29 
Response to initial treatment    
 CR or PR 22 85 
.063 
 SD or PD 6 8 
 Not evaluated 0 1  
Subsequent chemotherapy    
 Yes 12 60 
.044* 
 No 15 31 
 Unknown 1 3  
Pneumonitis associated with chemotherapy    
 Yes 8 2 
.0001* 
 No 20 92 
* Statistically significant with the χ
2
 test or Fisher’sexacttest; P < .05. 
Abbreviations; ILD = interstitial lung disease; ECOG PS = Eastern Cooperative Oncology Group 
Performance Status; LD = limited disease; ED = extensive disease; %VC = percent vital capacity; 
FEV1 = forced expiratory volume in one second; FVC = forced vital capacity; CR = complete 
response; PR = partial response; SD = stable disease; PD = progressive disease. 
 







Total 8/28 (28.6%) 2/94 (2.1%) .0001* 
First-line chemotherapy 5/28 (17.9%) 1/94 (1.1%) .0024* 
  Platinum plus etoposide 4/25 (16.0%) 1/65 (1.5%) .020* 
  Platinum plus irinotecan 1/3 (33.3%) 0/29 (0%) .094 
Subsequent chemotherapy 3/12 (25%) 1/60 (1.7%) .013* 
 Amrubicin 2/9 (22.2%) 1/59 (1.7%) .045* 
 Paclitaxel 1/1 (100.0%) 0/7 (0.0%) .13 
* Statistically significant with the χ
2
 test or Fisher’sexacttest; P < .05 
Abbreviations; ILD = interstitial lung disease. 
Table 4. (A) Univariate and multivariate analyses for overall survival in all patients (n = 122). (B) Univariate and multivariate analyses for overall 
survival in patients who received chemotherapy alone (n = 87). 
 
Univariate analysis  Multivariate analysis 
HR 95% CI P-value  HR 95% CI P-value 
(A) Variables        
Age (<75/>75 years) 0.88 0.54 – 1.51 .64  0.91 0.53 – 1.62 .75 
Gender (female/male) 0.90 0.50 – 1.54 .72  0.68 0.35 – 1.24 .21 
Smoking status (<40/>40 pack-years) 1.25 0.69 – 2.13 .45  1.28 0.68 – 2.30 .43 
ECOG PS (0 or 1/2 or 3) 0.20 0.11 – 0.37 < .0001*  0.19 0.10 – 0.37 < .0001* 
Stage (LD/ED) 0.35 0.20 – 0.59 < .0001*  0.42 0.23 – 0.73 .0017* 
Preexisting ILD (no/yes) 0.40 0.23 – 0.72 .0030*  0.36 0.19 – 0.69 .0027* 
(B) Variables        
Age (<75/>75 years) 0.75 0.45 – 1.31 .31  0.74 0.41 – 1.37 .34 
Gender (female/male) 0.76 0.39 – 1.36 .36  0.68 0.34 – 1.31 .26 
Smoking status (<40/>40 pack-years) 1.08 0.59 – 1.87 .79  1.16 0.61 – 2.12 .63 
ECOG PS (0 or 1/2 or 3) 0.26 0.14 – 0.49 < .0001*  0.18 0.095 – 0.36 < .0001* 
Stage (LD/ED) 0.88 0.43 – 1.63 .70  0.80 0.38 – 1.56 .52 
Preexisting ILD (no/yes) 0.53 0.30 – 0.96 .037*  0.44 0.23 – 0.87 .020* 
* Statistically significant with logistic regression model analysis; P < .05. 
Abbreviations; ECOG PS = Eastern Cooperative Oncology Group Performance Status; LD = limited disease; ED = extensive disease; ILD = interstitial 
lung disease; HR = hazard ratio; CI = confidence interval 
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